Outlook Therapeutics (OTLK) Cash & Current Investments: 2015-2020
Historic Cash & Current Investments for Outlook Therapeutics (OTLK) over the last 5 years, with Jun 2020 value amounting to $24.0 million.
- Outlook Therapeutics' Cash & Current Investments rose 70.77% to $24.0 million in Q2 2020 from the same period last year, while for Jun 2020 it was $38.0 million, marking a year-over-year increase of 135.35%. This contributed to the annual value of $8.0 million for FY2019, which is 366.73% up from last year.
- As of Q2 2020, Outlook Therapeutics' Cash & Current Investments stood at $24.0 million, which was up 414.80% from $4.7 million recorded in Q1 2020.
- Outlook Therapeutics' Cash & Current Investments' 5-year high stood at $24.0 million during Q2 2020, with a 5-year trough of $81,049 in Q1 2017.
- Over the past 3 years, Outlook Therapeutics' median Cash & Current Investments value was $5.3 million (recorded in 2018), while the average stood at $7.2 million.
- Per our database at Business Quant, Outlook Therapeutics' Cash & Current Investments crashed by 98.97% in 2017 and then spiked by 8,332.33% in 2018.
- Quarterly analysis of 5 years shows Outlook Therapeutics' Cash & Current Investments stood at $2.1 million in 2016, then surged by 565.75% to $13.8 million in 2017, then slumped by 98.35% to $227,716 in 2018, then skyrocketed by 485.62% to $1.3 million in 2019, then surged by 70.77% to $24.0 million in 2020.
- Its Cash & Current Investments stands at $24.0 million for Q2 2020, versus $4.7 million for Q1 2020 and $1.3 million for Q4 2019.